{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:23:31Z","timestamp":1792225411984,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10142-026-02030-8","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:37:27Z","timestamp":1789097847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated molecular and immune profiling identifies FOXA1 as a complementary co-target to MUC1 for bispecific immunotherapy in breast cancer"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7515-770X","authenticated-orcid":false,"given":"Debolina","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1055-1485","authenticated-orcid":false,"given":"Subhadip","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir Kumar","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2030_CR1","doi-asserted-by":"publisher","unstructured":"Anwar S, Zafar M, Hussain MA, Iqbal N, Ali A, Sadaf, et al. Unravelling the therapeutic potential of forkhead box proteins in breast cancer: An update (Review). Oncol Rep 2024;52:92. https:\/\/doi.org\/10.3892\/OR.2024.8751","DOI":"10.3892\/OR.2024.8751"},{"key":"2030_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/BPH.70390;WEBSITE:WEBSITE:BPSPUBS;WGROUP:STRING:PUBLICATION","author":"\u00c1 Bartha","year":"2026","unstructured":"Bartha \u00c1, Gy\u0151rffy B (2026) TNMplot: An enhanced platform for pharmacological target identification through cross-stage and pan-cancer gene expression analysis. Br J Pharmacol. https:\/\/doi.org\/10.1111\/BPH.70390;WEBSITE:WEBSITE:BPSPUBS;WGROUP:STRING:PUBLICATION","journal-title":"Br J Pharmacol"},{"key":"2030_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/J.NEO.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M et al (2022) UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25:18\u201327. https:\/\/doi.org\/10.1016\/J.NEO.2022.01.001","journal-title":"Neoplasia"},{"key":"2030_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/BFGP\/ELW018","volume":"15","author":"DP Chen","year":"2016","unstructured":"Chen DP, Lin YC, Fann CSJ (2016) Methods for identifying differentially methylated regions for sequence- and array-based data. Brief Funct Genomics 15:485\u2013490. https:\/\/doi.org\/10.1093\/BFGP\/ELW018","journal-title":"Brief Funct Genomics"},{"key":"2030_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/J.XPRO.2022.101232","volume":"3","author":"N de Prisco","year":"2022","unstructured":"de Prisco N, Botta S, Lee W, Rezazadeh S, Chemiakine A, Gennarino VA (2022) Determining the effects of loss of function mutations in human cell lines. STAR Protoc 3:101232. https:\/\/doi.org\/10.1016\/J.XPRO.2022.101232","journal-title":"STAR Protoc"},{"key":"2030_CR6","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.31557\/APJCP.2019.20.12.3763","volume":"20","author":"OS El-Masry","year":"2019","unstructured":"El-Masry OS, Brown BL, Dobson PRM (2019) AMPK activation of apoptotic markers in human breast cancer cell lines with different p53 backgrounds: MCF-7, MDA-MB-231 and T47D cells. Asian Pac J Cancer Prev 20:3763. https:\/\/doi.org\/10.31557\/APJCP.2019.20.12.3763","journal-title":"Asian Pac J Cancer Prev"},{"key":"2030_CR7","doi-asserted-by":"publisher","first-page":"101599","DOI":"10.1016\/J.LANEPE.2026.101599","volume":"64","author":"E Fontana","year":"2026","unstructured":"Fontana E, Grochot R, Kotecki N, Doger B, Nannini S, de Miguel M (2026) Evolution of bispecific and multispecific antibodies in cancer therapy. Lancet Reg Health - Europe 64:101599. https:\/\/doi.org\/10.1016\/J.LANEPE.2026.101599","journal-title":"Lancet Reg Health - Europe"},{"key":"2030_CR8","doi-asserted-by":"publisher","unstructured":"Genome IT\u2013 ICGAMIC, Dhup S, Singh A. The Indian Cancer Genome Atlas: A Multi-Omics Resource for Advancing Cancer Research. BioRxiv 2025:2025.03.25.645286. https:\/\/doi.org\/10.1101\/2025.03.25.645286","DOI":"10.1101\/2025.03.25.645286"},{"key":"2030_CR9","doi-asserted-by":"publisher","unstructured":"G\u00f3mez-Herranz M, Pilch M, Hupp T, Kote S. Interferon gamma, MHC class I regulation and immunotherapy. J Cell Signal. 2022;3(1):28-39. https:\/\/doi.org\/10.33696\/SIGNALING.3.065","DOI":"10.33696\/SIGNALING.3.065"},{"issue":"9","key":"2030_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00403-020-02059-0","volume":"312","author":"JJ Gong","year":"2020","unstructured":"Gong JJ, Margolis DJ, Monos DS (2020) Predictive in silico binding algorithms reveal HLA specificities and autoallergen peptides associated with atopic dermatitis. Arch Dermatol Res 312(9):647\u2013656. https:\/\/doi.org\/10.1007\/s00403-020-02059-0","journal-title":"Arch Dermatol Res"},{"key":"2030_CR11","doi-asserted-by":"publisher","unstructured":"Gopalkrishnan L, Patil S, Chhaya S, Badwe R, Joshi N (2006) HLA alleles in pre-menopausal breast cancer patients from western India. Indian J Medic Res 24(3):305-12. https:\/\/doi.org\/10.25259\/IJMR_20061243_305","DOI":"10.25259\/IJMR_20061243_305"},{"issue":"1","key":"2030_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01016-2","volume":"9","author":"US Grewal","year":"2025","unstructured":"Grewal US, Kurzrock R (2025) Mucin-1: a promising pan-cancer therapeutic target. NPJ Precis Oncol 9(1):218-. https:\/\/doi.org\/10.1038\/s41698-025-01016-2","journal-title":"NPJ Precis Oncol"},{"key":"2030_CR13","unstructured":"GSE89116 - Genome wide expression profiles of early and late onset breast cancers - OmicsDI n.d. https:\/\/www.omicsdi.org\/dataset\/geo\/GSE89116. Accessed 22 Apr 2026."},{"key":"2030_CR14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/BIOINFORMATICS\/BTAB806","volume":"38","author":"Z Gu","year":"2022","unstructured":"Gu Z, H\u00fcbschmann D (2022) Make interactive complex heatmaps in R. Bioinformatics 38:1460\u20131462. https:\/\/doi.org\/10.1093\/BIOINFORMATICS\/BTAB806","journal-title":"Bioinformatics"},{"key":"2030_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147025","volume":"131","author":"Y He","year":"2021","unstructured":"He Y, Wang L, Wei T, Xiao YT, Sheng H, Su H et al (2021) FOXA1 overexpression suppresses interferon signaling and immune response in cancer. J Clin Invest 131:e147025. https:\/\/doi.org\/10.1172\/JCI147025","journal-title":"J Clin Invest"},{"issue":"9","key":"2030_CR16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuc\u00e1 G et al (2021) Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer 2(9):904\u2013918. https:\/\/doi.org\/10.1038\/s43018-021-00244-2","journal-title":"Nat Cancer"},{"issue":"5","key":"2030_CR17","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/S10238-022-00978-Y","volume":"23","author":"W Jin","year":"2022","unstructured":"Jin W, Zhang M, Dong C, Huang L, Luo Q (2022) The multifaceted role of MUC1 in tumor therapy resistance. Clin Exp Med 23(5):1441\u20131474. https:\/\/doi.org\/10.1007\/S10238-022-00978-Y","journal-title":"Clin Exp Med"},{"key":"2030_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/DDC3040040","volume":"3","author":"BP Jit","year":"2024","unstructured":"Jit BP, Behera A, Qazi S, Mittal K, Kundu S, Bansal B et al (2024) Notch3 and its clinical importance in ovarian cancer. Drugs and Drug Candidates 3:707\u2013722. https:\/\/doi.org\/10.3390\/DDC3040040","journal-title":"Drugs and Drug Candidates"},{"key":"2030_CR19","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/JIMMUNOL.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M (2017) NetMHCpan 4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol 199:3360. https:\/\/doi.org\/10.4049\/JIMMUNOL.1700893","journal-title":"J Immunol"},{"issue":"1","key":"2030_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41523-025-00750-x","volume":"11","author":"SK Karthikeyan","year":"2025","unstructured":"Karthikeyan SK, Chandrashekar DS, Sahai S, Shrestha S, Aneja R, Singh R et al (2025) MammOnc-DB, an integrative breast cancer data analysis platform for target discovery. NPJ Breast Cancer 11(1):35. https:\/\/doi.org\/10.1038\/s41523-025-00750-x","journal-title":"NPJ Breast Cancer"},{"key":"2030_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/J.CRITREVONC.2026.105231","volume":"221","author":"MS Khan","year":"2026","unstructured":"Khan MS, Almalki WH (2026) Molecular alterations of MUC1 and their therapeutic exploitation: emerging opportunities in cancer therapy. Crit Rev Oncol Hematol 221:105231. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2026.105231","journal-title":"Crit Rev Oncol Hematol"},{"key":"2030_CR22","doi-asserted-by":"publisher","unstructured":"Kumar S, Kundu S, Sharawat SK, Sharma A. Rewiring cancer epigenome: lncRNA as modulator of chromatin architecture and neoplastic transformation. Mammalian Genome 2025 37:1 2025;37:3-. https:\/\/doi.org\/10.1007\/s00335-025-10172-6","DOI":"10.1007\/s00335-025-10172-6"},{"key":"2030_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jgg.2021.02.004","volume":"48","author":"S Kundu","year":"2021","unstructured":"Kundu S, Ray MD, Sharma A (2021) Interplay between genome organization and epigenomic alterations of pericentromeric DNA in cancer. J Genet Genomics 48:184\u2013197. https:\/\/doi.org\/10.1016\/j.jgg.2021.02.004","journal-title":"J Genet Genomics"},{"issue":"1","key":"2030_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00335-024-10086-9","volume":"36","author":"S Kundu","year":"2024","unstructured":"Kundu S, Jit BP, Sharma A (2024) Pan-cancer TCGA analysis reveals the potential involvement of B-type lamins in dysregulating chromosome segregation in human cancer. Mamm Genome 36(1):230\u2013249. https:\/\/doi.org\/10.1007\/s00335-024-10086-9","journal-title":"Mamm Genome"},{"key":"2030_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-44020-7","author":"S Kundu","year":"2026","unstructured":"Kundu S, Akhtar AR, Kumar A, Sharma A (2026) SUV family histone methyltransferases correlate with nuclear lamina remodeling and clinical outcome in cancer: integrative pan-cancer TCGA analysis and experimental evidence. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-026-44020-7","journal-title":"Sci Rep"},{"key":"2030_CR26","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/NAR\/GKW329","volume":"44","author":"A Lamiable","year":"2016","unstructured":"Lamiable A, Thevenet P, Rey J, Vavrusa M, Derreumaux P, Tuffery P (2016) PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Res 44:W449\u2013W454. https:\/\/doi.org\/10.1093\/NAR\/GKW329","journal-title":"Nucleic Acids Res"},{"key":"2030_CR27","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307\/SUPPLEMENTARY-VIDEO-S1","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS et al (2017) TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res 77:e108\u2013e110. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0307\/SUPPLEMENTARY-VIDEO-S1","journal-title":"Cancer Res"},{"key":"2030_CR28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/IMM.13168","volume":"159","author":"Z Li","year":"2020","unstructured":"Li Z, Gong H, Liu Q, Wu W, Cheng J, Mei Y et al (2020) Identification of an HLA-A*24:02-restricted \u03b1-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy. Immunology 159:384. https:\/\/doi.org\/10.1111\/IMM.13168","journal-title":"Immunology"},{"key":"2030_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/BIOM12070952","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Yang D, Guo T, Lin M (2022) Advances in MUC1-mediated breast cancer immunotherapy. Biomolecules (Basel) 12:952. https:\/\/doi.org\/10.3390\/BIOM12070952","journal-title":"Biomolecules (Basel)"},{"issue":"1","key":"2030_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02455-3","volume":"11","author":"X Li","year":"2025","unstructured":"Li X, Chen Y, Lan R, Liu P, Xiong K, Teng H et al (2025) Transmembrane mucins in lung adenocarcinoma: understanding of current molecular mechanisms and clinical applications. Cell Death Discov 11(1):163-. https:\/\/doi.org\/10.1038\/s41420-025-02455-3","journal-title":"Cell Death Discov"},{"issue":"1","key":"2030_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41420-024-01936-1","volume":"10","author":"N Liu","year":"2024","unstructured":"Liu N, Wang A, Xue M, Zhu X, Liu Y, Chen M (2024a) FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer. Cell Death Discovery 10(1):172. https:\/\/doi.org\/10.1038\/s41420-024-01936-1","journal-title":"Cell Death Discovery"},{"issue":"1","key":"2030_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01955-5","volume":"9","author":"Z Liu","year":"2024","unstructured":"Liu Z, Chen J, Ren Y, Liu S, Ba Y, Zuo A et al (2024b) Multi-stage mechanisms of tumor metastasis and therapeutic strategies. Signal Transduct Target Ther 9(1):270-. https:\/\/doi.org\/10.1038\/s41392-024-01955-5","journal-title":"Signal Transduct Target Ther"},{"key":"2030_CR33","doi-asserted-by":"publisher","unstructured":"Long L, Huang X, Yu S, Fan J, Li X, Xu R, et al. The research status and prospects of MUC1 in immunology. Hum Vaccin Immunother 2023;19. https:\/\/doi.org\/10.1080\/21645515.2023.2172278","DOI":"10.1080\/21645515.2023.2172278"},{"key":"2030_CR34","doi-asserted-by":"publisher","unstructured":"Maino A, Bourov A-Flin E, Decaens T, et al. Identification of immunogenic HLA-A*02:01 epitopes associated with HCC for immunotherapy development.\u00a0Hepatol Commun. 2025;9(3):e0659. https:\/\/doi.org\/10.1097\/HC9.0000000000000659","DOI":"10.1097\/HC9.0000000000000659"},{"key":"2030_CR35","doi-asserted-by":"publisher","unstructured":"Menon SMP, Elengoe A. Evaluation of the role of kras gene in colon cancer pathway using string and Cytoscape software. Biomedical Research and Therapy 2020;7:3835\u201342. https:\/\/doi.org\/10.15419\/BMRAT.V7I6.612","DOI":"10.15419\/BMRAT.V7I6.612"},{"key":"2030_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/S12967-025-06786-8","volume":"23","author":"VP Nimbalkar","year":"2025","unstructured":"Nimbalkar VP, Snijesh VP, Rajarajan S, Anupama CE, Mahalakshmi S, Alexander A et al (2025) Spatial profiling reveals unique immune microenvironment in premenopausal triple-negative breast cancer associated with therapy response. J Transl Med 23:761. https:\/\/doi.org\/10.1186\/S12967-025-06786-8","journal-title":"J Transl Med"},{"issue":"1","key":"2030_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/S44178-026-00257-W","volume":"5","author":"K Qian","year":"2026","unstructured":"Qian K, Zhang Y, Zhou Q, Zhou J, Wu X, Zhu J et al (2026) MUC1 in cancer. Holistic Integrat Oncol 5(1):32. https:\/\/doi.org\/10.1007\/S44178-026-00257-W","journal-title":"Holistic Integrat Oncol"},{"key":"2030_CR38","doi-asserted-by":"publisher","unstructured":"Rajabzadeh A, Ahmadvand D, Salmani MK, Rahbarizadeh F, Hamidieh AA. A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells. Cell Journal (Yakhteh) 2020;22:502. https:\/\/doi.org\/10.22074\/CELLJ.2021.6917","DOI":"10.22074\/CELLJ.2021.6917"},{"key":"2030_CR39","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.3390\/CANCERS15235632","volume":"15","author":"PS Rana","year":"2023","unstructured":"Rana PS, Ignatz-Hoover JJ, Driscoll JJ (2023) Targeting proteasomes and the MHC class I antigen presentation machinery to treat cancer, infections and age-related diseases. Cancers (Basel) 15:5632. https:\/\/doi.org\/10.3390\/CANCERS15235632","journal-title":"Cancers (Basel)"},{"key":"2030_CR40","doi-asserted-by":"publisher","unstructured":"Roy A, Niharika, Kesarwani V, Shankar R, Patra SK. A Comprehensive Gene Expression Analysis of Extensive Cohorts From Colon Adenocarcinoma Uncovered a Set of Genes Regulated by DNA Hypomethylation and Predominantly Influenced by Lipid Raft-Mediated EGFR-RAS-MAPK Signaling. Mol Carcinog 2026;65:465\u201392. https:\/\/doi.org\/10.1002\/MC.70085;CTYPE:STRING:JOURNAL","DOI":"10.1002\/MC.70085;CTYPE:STRING:JOURNAL"},{"key":"2030_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-023-36062-6","author":"B Ru","year":"2023","unstructured":"Ru B, Huang J, Zhang Y, Aldape K, Jiang P (2023) Estimation of cell lineages in tumors from spatial transcriptomics data. Nat Commun. https:\/\/doi.org\/10.1038\/S41467-023-36062-6","journal-title":"Nat Commun"},{"key":"2030_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/J.BEHA.2024.101559","volume":"37","author":"A Sanchez-Mazas","year":"2024","unstructured":"Sanchez-Mazas A, Nunes JM, Di D, Dominguez EA, Gerbault P, Faye NK et al (2024) The most frequent HLA alleles around the world: a fundamental synopsis. Best Pract Res Clin Haematol 37:101559. https:\/\/doi.org\/10.1016\/J.BEHA.2024.101559","journal-title":"Best Pract Res Clin Haematol"},{"key":"2030_CR43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/02611929231193416;SUBPAGE:STRING:ABSTRACT;REQUESTEDJOURNAL:JOURNAL:ATLA;WEBSITE:WEBSITE:SAGE;WGROUP:STRING:PUBLICATION","volume":"51","author":"S Saravanakumar","year":"2023","unstructured":"Saravanakumar S, Chatterjee J (2023) The Use of In Silico Methods to Identify and Assess Antigenic Regions Suitable for the Development of Peptide-based Pan-viral Vaccines. Altern Lab Anim 51:313\u2013322. https:\/\/doi.org\/10.1177\/02611929231193416;SUBPAGE:STRING:ABSTRACT;REQUESTEDJOURNAL:JOURNAL:ATLA;WEBSITE:WEBSITE:SAGE;WGROUP:STRING:PUBLICATION","journal-title":"Altern Lab Anim"},{"key":"2030_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/TAN.13447;WGROUP:STRING:PUBLICATION","volume":"93","author":"A Saxena","year":"2019","unstructured":"Saxena A, Sharma G, Tyagi S, Mourya M, Coshic P, Tiwari PK et al (2019) HLA-A*02 repertoires in three defined population groups from North and Central India: Punjabi Khatries. Kashmiri Brahmins and Sahariya Tribe HLA 93:16\u201323. https:\/\/doi.org\/10.1111\/TAN.13447;WGROUP:STRING:PUBLICATION","journal-title":"Kashmiri Brahmins and Sahariya Tribe HLA"},{"key":"2030_CR45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/S12943-025-02390-Y","volume":"24","author":"L Shui","year":"2025","unstructured":"Shui L, Wu D, Yang K, Sun C, Li Q, Yin R (2025) Bispecific antibodies: unleashing a new era in oncology treatment. Mol Cancer 24:212. https:\/\/doi.org\/10.1186\/S12943-025-02390-Y","journal-title":"Mol Cancer"},{"key":"2030_CR46","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.12688\/F1000RESEARCH.9005.3","volume":"5","author":"GK Smyth","year":"2018","unstructured":"Smyth GK, Ritchie ME, Law CW, Alhamdoosh M, Su S, Dong X et al (2018) RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR. F1000Res 5:1408. https:\/\/doi.org\/10.12688\/F1000RESEARCH.9005.3","journal-title":"F1000Res"},{"key":"2030_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/S40425-015-0089-6","volume":"3","author":"S Spranger","year":"2015","unstructured":"Spranger S, Gajewski TF (2015) A new paradigm for tumor immune escape: \u03b2-catenin-driven immune exclusion. J Immunother Cancer 3:43. https:\/\/doi.org\/10.1186\/S40425-015-0089-6","journal-title":"J Immunother Cancer"},{"key":"2030_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1313371","volume":"6","author":"A Tosi","year":"2017","unstructured":"Tosi A, Dalla Santa S, Cappuzzello E, Marotta C, Walerich D, Del Sal G et al (2017) Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. Oncoimmunology 6:e1313371. https:\/\/doi.org\/10.1080\/2162402X.2017.1313371","journal-title":"Oncoimmunology"},{"issue":"1","key":"2030_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w","volume":"14","author":"A Trabolsi","year":"2024","unstructured":"Trabolsi A, Arumov A, Schatz JH (2024) Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J 14(1):27-. https:\/\/doi.org\/10.1038\/s41408-024-00997-w","journal-title":"Blood Cancer J"},{"issue":"1","key":"2030_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang CH, Li N (2025) Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther 10(1):227-. https:\/\/doi.org\/10.1038\/s41392-025-02280-1","journal-title":"Signal Transduct Target Ther"},{"key":"2030_CR51","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.7150\/IJBS.108036","volume":"21","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang M, Wang M, Zhou R, Deng X, Ouyang X et al (2025) From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy. Int J Biol Sci 21:2676. https:\/\/doi.org\/10.7150\/IJBS.108036","journal-title":"Int J Biol Sci"}],"container-title":["Functional & Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-02030-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-026-02030-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-026-02030-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:37:29Z","timestamp":1789097849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-026-02030-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2030"],"URL":"https:\/\/doi.org\/10.1007\/s10142-026-02030-8","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"value":"1438-793X","type":"print"},{"value":"1438-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"259"}}